# MoleculeMind

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/moleculemind

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.moleculemind.com
- Latest round: Series A (Jun 17, 2026)
- Investors on record: 20

## About

Based in Beijing, China, and founded in 2022, MoleculeMind Inc., doing business named MoleculeMind, is a biopharmaceutical company that focuses on the fields of artificial intelligence (AI) protein design. Professor Xu Jinbo, the company's founder, served as a professor at the University of Chicago. The company has cooperated with National Labs, the Chinese Academy of Sciences, and other research institutions to establish the dry and wet labs. It also collaborated with pharmacy corporation, such as Merck, and Roche, to explore AI drug research for gene therapy, and antibody therapy. In June 2026, it closed a series A funding round.

MoleculeMind developed an AI macromolecule optimization and design platform, MoleculeOS, which uses a data-driven deep learning approach to help biotechnologists identify and generate proteins. The platform can be used for research and design of peptides, antibodies, enzymes, and small proteins and for protein optimization and design in chemistry, materials, synthetic biology, industry, agriculture, and other fields. 

The company generates revenue through AI protein design platforms, software and API-based tools, technical services, and industry-specific design solutions for life sciences and industrial biotechnology users.

## Funding rounds

- Series A, Jun 17, 2026 — Infinity Group, Oriental Fortune Capital, COFCO Agricultural Industry Fund Management, Cathay Biotech Inc., Fosun Capital, Caixin Capital, Sepax Technologies, Inc., Shanghai Growth Investment, Pudong Venture Capital, Blue Bridge Holdings, Neux Capital, Zhengding Investment
- Series A, Sep 13, 2024 — EBI Investment, Cher Ami Wealth & Financial, Shenzhen Capital Real Estate Fund, Sense Capital
- Angel, Apr 18, 2022 — Hong Shan, Baidu Ventures, Future Qichuang Capital, Beijing Life Science Park Innovation Investment Fund, Neux Capital

## Investors

- Hong Shan — Angel
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Angel
- Future Qichuang Capital (https://capitalatlas.ai/funds/future-qichuang-capital) — Angel
- Beijing Life Science Park Innovation Investment Fund — Angel
- Neux Capital — Angel, Series A
- EBI Investment (https://capitalatlas.ai/funds/ebi-investment) — Series A
- Cher Ami Wealth & Financial — Series A
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A
- Sense Capital (https://capitalatlas.ai/funds/sense-capital) — Series A
- Infinity Group (https://capitalatlas.ai/funds/infinity-group) — Series A
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series A
- COFCO Agricultural Industry Fund Management (https://capitalatlas.ai/funds/cofco-agricultural-industry-fund-management) — Series A
- Cathay Biotech Inc. — Series A
- Fosun Capital (https://capitalatlas.ai/funds/fosun-capital) — Series A
- Caixin Capital (https://capitalatlas.ai/funds/caixin-capital) — Series A
- Sepax Technologies, Inc. — Series A
- Shanghai Growth Investment (https://capitalatlas.ai/funds/shanghai-growth-investment) — Series A
- Pudong Venture Capital (https://capitalatlas.ai/funds/pudong-venture-capital) — Series A
- Blue Bridge Holdings (https://capitalatlas.ai/funds/blue-bridge-holdings) — Series A
- Zhengding Investment — Series A